Effectiveness of 0.3% Hyaluronic Acid Eye Drops in the Treatment of Benign Essential Blepharospasm and Hemifacial Spasm

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20220423002

Enrollment

Registered

2022-04-23

Start date

2020-04-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with benign essential blepharospasm (BEB) or hemifacial spasm (HFS) during concurrent treatment with botulinum toxin type A (BoNT-A) injection benign essential blepharospasm hemifacial spasm dry eye disease 0.3% hyaluronic acid botulinum toxin

Interventions

The 0.3% purified sodium hyaluronate (HA) was used as a treatment intervention. Patients were instructed to apply 0.3% HA eye drops to both eyes at 4-hour intervals for 3 months consecutively.,Patient

Active Comparator Drug,No Intervention No treatment

0.3% Hyaluronic Acid Eye Drops,No intervention

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with the diagnosis of BEB or HFS who were concurrently treated with BoNT-A injections, regardless of dry eye symptoms, and willing to enroll in the study.

Exclusion criteria

Exclusion criteria: 1. neurological abnormalities other than craniocervical dystonia 2. features suggestive of secondary dystonias 3. history of other active ocular surface disorders or anterior segment diseases 4. ocular trauma or eyelid/ocular surgery in the preceding 6 months 5. contact lens wear 6. concurrent application of any type(s) of artificial tears or other treatments for DED in the preceding 3 months.

Design outcomes

Primary

Measure	Time frame
Changes in spasm severity 3 months after instillation of eye drops Blepharospasm Severity Scale (BSS) score in patients with BEB; Samsung Medical Class (SMC) Grading Scale score in patients with HFS	—

Secondary

Measure	Time frame
Changes in dry eye parameters 3 months after instillation of eye drops dry eye symptoms, lower lid tear meniscus height, tear break-up time, and corneal fluorescein stain in all patients	—

Countries

Thailand

Contacts

Public ContactNanida Tiraset

Department of Ophthalmology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, THAILAND

tiraset.n@gmail.com0810819345

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026